title: Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia.
abstract: BACKGROUND
  IV/PO moxifloxacin was evaluated in the treatment of hospitalized patients with severe community-acquired pneumonia (CAP).
  
  
  METHODS
  Data were pooled from two prospective, randomized studies. In the multinational study, patients received 7-14 days IV/PO moxifloxacin 400 mg QD or IV/ PO amoxicillin clavulanate 1200/625 mg TID +/- IV/PO clarithromycin 500 mg BID. In the North American study, patients received 7-14 days IV/PO moxifloxacin 400 mg QD, IV/ PO alatrofloxacin/trovafloxacin 200 mg QD, or IV/PO levofloxacin 500 mg QD. The primary endpoint was clinical success at the test-to-cure visit. Severe CAP was defined according to the 1993 ATS criteria.
  
  
  RESULTS
  In the clinically valid population, clinical success rates were 88% (167/190) for moxifloxacin- and 83% (155/186) for comparator-treated patients (95% CI = -1.9%, 12.2%). Corresponding clinical success rates for the microbiologically valid population were 87% (59/68) and 84% (54/64), respectively (95% CI = 8.6%, 15.0%). A switch from IV to PO therapy was made by day 5 of therapy for 73% of moxifloxacin- vs. 60% of comparator-treated patients (P < 0.01). Clinical success rates were similar in a retrospective analysis using the revised 2001 ATS definition of severe CAP. Mortality rates were 6% (15/241) and 10% (24/238) in the moxifloxacin and comparator treatment groups, respectively. The incidence of drug-related adverse events was similar in both treatment groups.
  
  
  CONCLUSIONS
  Sequential IV/PO moxifloxacin 400 mg QD is as safe and effective as other fluoroquinolones and a beta-lactam/macrolide combination for treating hospitalized patients with severe CAP.
authors.affiliation: Zentralklinik Emil von Behring, Lungenklinik Heckeshorn, Berlin 10115, Germany. haloheck@zedat.fu-berlin.de
authors.forename: H
authors.initials: H
authors.lastname: Lode
authors.forename: C
authors.initials: C
authors.lastname: Grossman
authors.forename: S
authors.initials: S
authors.lastname: Choudhri
authors.forename: D
authors.initials: D
authors.lastname: Haverstock
authors.forename: J
authors.initials: J
authors.lastname: McGivern
authors.forename: Z
authors.initials: Z
authors.lastname: Herman-Gnjidic
authors.forename: D
authors.initials: D
authors.lastname: Church
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001372:Aza Compounds / Q000008:administration & dosage / Q000009:adverse effects; D017291:Clarithromycin / Q000008:administration & dosage / Q000009:adverse effects; D017714:Community-Acquired Infections / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D024841:Fluoroquinolones / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077266:Moxifloxacin; D009287:Naphthyridines / Q000008:administration & dosage / Q000009:adverse effects; D018410:Pneumonia, Bacterial / Q000188:drug therapy*; D011804:Quinolines / Q000008:administration & dosage / Q000009:adverse effects; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D001372:Aza Compounds; D024841:Fluoroquinolones; D009287:Naphthyridines; D011804:Quinolines; C106856:alatrofloxacin; C080163:trovafloxacin; D017291:Clarithromycin; D000077266:Moxifloxacin